Olema Pharmaceuticals inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 23.09, 121.76, 294.8, 536.62 ], "ebit_estimate": [ -244.23, -272.7, -232.62, -144.28, 29.17 ], "ebitda_estimate": [ -233.74, -265.85, -194.55, -65.75, null ], "net_income_estimate": [ -225.45, -258.16, -222.71, -126.41, 42.91 ], "per_share_eps_estimate": [ -2.24, -2.53, -2.2, -1.09, 0.35 ], "eps_nri_estimate": [ -2.22, -2.44, -2.07, -1.09, 0.35 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.92, 2.58, 2.26, null, null ], "pretax_income_estimate": [ -219.76, -246.05, -202.49, -48.88, 179.88 ], "operating_cash_flow_per_share_estimate": [ -1.97, -2.14, -1.83, null, null ], "roa_estimate": [ -40.1, -46.6, null, null, null ], "roe_estimate": [ -49.72, -85.72, -97.1, null, null ], "gross_margin_estimate": [ 89, 89.5, 90, 93, 92 ], "operating_cash_flow_estimate": [ -202.52, -219.48, -188.12, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 34.24 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -9.43, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -11.43, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -28.02, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -41.5, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, 3.33, 10.85 ], "ebit_estimate": [ -58.81, -62.12, -66.35, -61.08, -65.07, -66.05, -64.85 ], "ebitda_estimate": [ -56.85, -59.4, -61.85, -54.71, null, null, null ], "net_income_estimate": [ -55.16, -57.42, -62.25, -60.08, -62.76, -63.94, -62.77 ], "per_share_eps_estimate": [ -0.55, -0.57, -0.61, -0.57, -0.59, -0.61, -0.57 ], "eps_nri_estimate": [ -0.55, -0.56, -0.59, -0.6, -0.61, -0.63, -0.6 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -54.56, -55.72, -59.15, -60.08, -62.76, -63.94, -62.77 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -42.5, -38.25, -43.46, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, 89, 89, 89 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -9.43, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -11.43, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -28.02, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -41.5, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }